AVITA Medical, Inc.

NASDAQ:RCEL

Medical - Devices

Healthcare
$16.83 -0.25%

+$0.00 today

Market cap
$418.11M
Beta
1.86
P/E (TTM)
-0.0
EPS (TTM)
-$148.45
52W Low $3.22High $7.12

Volume 0.72M

Average 0.24M

RCEL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

AVITA Medical, Inc.NASDAQ: RCEL

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 81.7%

Gross margin was 81.7% in Q1 FY2026, down 3.0 pp from a year earlier. On a trailing-twelve-month basis it was 81.4%, down 4.1 pp year over year. Over 3 fiscal years it narrowed by 0.3 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
81.7%+0.5 pp QoQ
Last fiscal yearDec 2025
82.1%-3.7 pp YoY
LTMMar 2026
81.4%-4.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-3.0 pp——
1 year-3.7 pp——
3 years-0.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
82.1%
Year-over-year change
-3.7pp

Gross Margin vs competitors

How RCEL compares with its peers on the latest reported figures

  • RCEL's LTM Mar 2026 gross margin of 81.4% is the 2nd highest of the 8 companies compared; the peer median is 40.3%.
  • Its year-over-year change of -4.1 pp is the 6th highest of 8, against a peer median of -0.5 pp.
  • Over three fiscal years its change of -0.3 pp compares with a peer median of +7.5 pp.
RCEL Competitors Peer median
Gross Margin for RCEL and competitors
Company Period LTM level YoY 3-year change
OVIDOvid Therapeutics Inc.LTM Mar 202699.5% -0.5 pp-4.1 pp
RCELAVITA Medical, Inc.LTM Mar 202681.4% -4.1 pp-0.3 pp
XTNTXtant Medical Holdings, Inc.LTM Mar 202662.3% +4.2 pp+7.5 pp
HYPRHyperfine, Inc.LTM Mar 202651.2% +5.0 pp+36.5 pp
FONRFONAR CorporationLTM Mar 202640.3% -1.0 pp-7.1 pp
APYXApyx Medical CorporationLTM Mar 202632.3% -19.3 pp-29.4 pp
LUCDLucid Diagnostics Inc.LTM Mar 2026-40.0% +27.6 pp+798.4 pp
STTKShattuck Labs, Inc.LTM Mar 2026-82.0% -120.1 pp+12607.2 pp
VANIVivani Medical, Inc.FY2025— ——
Peer median (excluding RCEL) 40.3%-0.5 pp+7.5 pp

Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.03M34.42M50.14M64.25M71.61M
Cost of Revenue6.1M6.04M7.78M9.09M12.79M
Gross Profit26.92M28.38M42.36M55.16M58.82M
Gross Margin81.5%82.4%84.5%85.8%82.1%
Research & Development15.67M13.86M20.82M20.36M20.84M
Selling, General & Admin37.21M45.24M65.63M91.39M79.91M
Operating Expenses52.04M55.89M85.02M111.75M100.75M
Depreciation & Amortization673K568K632K1.13M2.35M
EBITDA(24.4M)(26.05M)(33.54M)(55.3M)(39.59M)
EBITDA Margin-73.9%-75.7%-66.9%-86.1%-55.3%
Operating Income(25.12M)(27.51M)(42.66M)(56.59M)(41.93M)
Operating Margin-76.1%-79.9%-85.1%-88.1%-58.6%
Interest Income00000
Interest Expense29K16K1.14M5.36M5M
Other Income / Expenses18K876K7.34M(5.2M)(6.64M)
Income Before Tax(25.1M)(26.63M)(35.32M)(61.79M)(48.58M)
Pre-Tax Margin-76.0%-77.4%-70.4%-96.2%-67.8%
Income Tax Expense42K36K66K54K11K
Net Income(25.14M)(26.67M)(35.38M)(61.85M)(48.59M)
Net Margin-76.1%-77.5%-70.6%-96.3%-67.8%
EPS (Basic)(1.03)(1.07)(1.40)(2.39)(1.74)
EPS (Diluted)(1.03)(1.07)(1.40)(2.39)(1.74)
Weighted Avg Shares24.36M25M25.33M25.88M27.86M
Weighted Avg Shares (Diluted)24.36M25M25.33M25.88M27.86M

AVITA Medical, Inc.

NASDAQ:RCEL

Intrinsic Alpha fair value

Locked

Current Price

$16.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.